BR112023001330A2 - N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
BR112023001330A2
BR112023001330A2 BR112023001330A BR112023001330A BR112023001330A2 BR 112023001330 A2 BR112023001330 A2 BR 112023001330A2 BR 112023001330 A BR112023001330 A BR 112023001330A BR 112023001330 A BR112023001330 A BR 112023001330A BR 112023001330 A2 BR112023001330 A2 BR 112023001330A2
Authority
BR
Brazil
Prior art keywords
benzohydrazide
methylbenzoyl
quinolyl
ethynyl
chloro
Prior art date
Application number
BR112023001330A
Other languages
Portuguese (pt)
Inventor
Krishnaji Damle Nitin
Nandlalhi Mandhane Sanjay
Ashokkumar Soni Durgesh
Kamalchand Jain Shakti
Krishna Ramanathan Vikram
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of BR112023001330A2 publication Critical patent/BR112023001330A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

N ¢-(2-CLORO-6-METILBENZOIL)-4-METIL-3-[2-(3-QUINOLIL)ETINIL]- BENZOHIDRAZIDA PARA TRATAMENTO DA DOENÇA DE ALZHEIMER. A presente invenção fornece um método para prevenir ou tratar a doença de Alzheimer e sintomas da mesma compreendendo a administração a um indivíduo em necessidade de uma quantidade terapeuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil)etinil]-benzohidrazida ou sais farmaceuticamente aceitáveis do mesmo, em que a prevenção e/ou tratamento da referida doença e sintomas da mesma é alcançado pela inibição de beta-amiloide (Aß) agregação de placa, hiperfosforilação de tau, c-Abl quinase ou uma combinação destes. Também é divulgado o uso de uma quantidade terapeuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil)etinil]-benzohidrazida ou sais farmaceuticamente aceitáveis do mesmo para inibir a agregação de placa beta-amiloide (Aß), hiperfosforilação de tau, c-Abl quinase ou uma combinação destes.N ¢-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE. The present invention provides a method of preventing or treating Alzheimer's disease and symptoms thereof comprising administering to a subject in need of it a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3 -[2-(3-quinolyl)ethynyl]-benzohydrazide or pharmaceutically acceptable salts thereof, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibiting beta-amyloid (Aß) plaque aggregation, hyperphosphorylation of tau, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or pharmaceutically acceptable salts thereof to inhibit beta-amyloid (Aß) plaque aggregation, tau hyperphosphorylation, c-Abl kinase, or a combination thereof.

BR112023001330A 2020-07-31 2021-07-30 N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE BR112023001330A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021032951 2020-07-31
PCT/IB2021/056986 WO2022024072A1 (en) 2020-07-31 2021-07-30 N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112023001330A2 true BR112023001330A2 (en) 2023-02-14

Family

ID=77265130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001330A BR112023001330A2 (en) 2020-07-31 2021-07-30 N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE

Country Status (12)

Country Link
US (1) US20230301982A1 (en)
EP (1) EP4188351A1 (en)
JP (1) JP2023536440A (en)
KR (1) KR20230047140A (en)
CN (1) CN116194098A (en)
AU (1) AU2021317186A1 (en)
BR (1) BR112023001330A2 (en)
CA (1) CA3185939A1 (en)
CL (1) CL2023000270A1 (en)
IL (1) IL300044A (en)
MX (1) MX2023001358A (en)
WO (1) WO2022024072A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5905028B2 (en) 2011-01-21 2016-04-20 スン プハルマ アドバンセド リサーチ カンパニー リミテド Tyrosine kinase inhibitors containing diarylacetylene hydrazides
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
JP7234129B2 (en) * 2017-03-15 2023-03-07 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド A novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid N'-(2-chloro-6-methyl-benzoyl)hydrazide

Also Published As

Publication number Publication date
AU2021317186A1 (en) 2023-03-16
KR20230047140A (en) 2023-04-06
CL2023000270A1 (en) 2023-09-29
IL300044A (en) 2023-03-01
WO2022024072A1 (en) 2022-02-03
JP2023536440A (en) 2023-08-25
CA3185939A1 (en) 2022-02-03
EP4188351A1 (en) 2023-06-07
CN116194098A (en) 2023-05-30
MX2023001358A (en) 2023-02-27
US20230301982A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
BR112022026899A2 (en) COMPOUND REPRESENTED BY FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A VIRAL INFECTION, METHOD OF INHIBITING VIRAL PROTEASE 3C OR VIRAL PROTEASE 3CL IN A MAMMAL, AND METHOD OF TREATMENT OF A DISORDER RESPIRATORY
Olszewski Episodic dermatolymphangioadenitis (DLA) in patients with lymphedema of the lower extremities before and after administration of benzathine penicillin: a preliminary study
BR112017017009A2 (en) uses of a formaldehyde scavenger and pharmaceutical composition, methods for preventing, delaying, slowing or slowing transformation of a compound and for treating cancer, and pharmaceutical composition.
BR112018016001A2 (en) pharmaceutical composition, treatment methods and uses thereof
BR112022009571A2 (en) USE OF FAK INHIBITOR IN THE PREPARATION OF A DRUG TO TREAT TUMORS THAT HAVE NRAS MUTATION
BR112022025805A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREAT OR PREVENT A DISORDER, CONDITION OR DISEASE
BR112015029491A2 (en) imidazopyrrolidinone derivatives and their use in the treatment of disease
BR112023002573A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF VIRAL INFECTION AND RESPIRATORY DISORDERS AND METHOD OF INHIBITION OF VIRAL PROTEASE
NO20090887L (en) Procedure for treating and preventing mucositis
BR112021024491A2 (en) Immunogenic composition, and method of preventing, treating or ameliorating an infection, disease or condition
BR112021017314A2 (en) USE OF ELAEOCARPUS SYLVESTRIS EXTRACT
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
BR112021021637A2 (en) Subunit vaccine for treating or preventing a respiratory tract infection
BR112023001330A2 (en) N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE
BR112021024845A2 (en) Combination for the treatment of infections caused by mycoplasma genitalium
BR112018017233A2 (en) i use. butyriciproducens and / or e. hallii and composition
CL2023001992A1 (en) Anti-n3pglu beta amyloid antibodies and their uses
BR112019002945A2 (en) Combination therapy for pancreatic cancer treatment
BR112018072298A2 (en) treatment of Zika virus infections using alpha-glucosidase inhibitors
BR112014004339A2 (en) oral suspension
BR112018010497A2 (en) synergistic combination of pyrrolidone carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of mucosal dryness and irritation and related pharmaceutical formulations
Wollina et al. Pharmacotherapy of pompholyx
BR112023001547A2 (en) PHARMACEUTICAL COMPOSITION COMPRISING LIRAGLUTIDE, OR GEFITINIB OR ONE OF THEIR SALTS OR SOLVATES, AND USE THEREOF
BR112018072164A2 (en) pharmaceutical composition, method for treating and / or preventing a patient's skin disease and / or alleviating the symptoms thereof, and cosmetic use of a composition
BR112022019338A2 (en) MIGRAINE PREVENTIVE TREATMENT